Guidelines for Phytonadione, Octreotide, and Acetylcysteine Administration and Y‑Site Compatibility

Phytonadione (Vitamin K₁) Administration

Oral vitamin K is the preferred route for most clinical scenarios because it offers superior safety and more predictable efficacy than intravenous administration. (American College of Cardiology) 1
Oral vitamin K should be used as the first‑line treatment for warfarin reversal unless rapid correction of anticoagulation is required for life‑threatening bleeding. (American College of Cardiology) 2
When intravenous vitamin K is unavoidable, give 5–10 mg diluted in 25–50 mL normal saline over 15–30 minutes (slow infusion) to reduce the risk of anaphylaxis. (American College of Cardiology) 1
Subcutaneous administration of vitamin K should be avoided because absorption is unpredictable and the therapeutic response is delayed. (American College of Cardiology) 2
Warfarin‑related INR reversal dosing:
- INR 5–9 → 1–2.5 mg orally.
- INR > 9 → 3–5 mg orally.
- Life‑threatening bleeding or INR > 20 → 10 mg IV as a slow infusion plus prothrombin‑complex concentrate.

Acute variceal hemorrhage: administer a 50 µg IV bolus followed by a continuous IV infusion of 50 µg/hour for 2–5 days.** (Gastroenterology) 3

Oral regimen: loading dose of 140 mg/kg, then 70 mg/kg every 4 hours for a total of 17 doses (≈72 hours).** (Annals of Emergency Medicine) 4
Hospital stocking recommendation for a 100‑kg patient: 22 g of acetylcysteine for an 8‑hour supply and 30 g for a 24‑hour supply.** (Annals of Emergency Medicine) 4

For definitive Y‑site compatibility information on phytonadione, octreotide, and acetylcysteine, consult Trissel’s Handbook on Injectable Drugs. (Annals of Emergency Medicine) 4
Institutional pharmacy departments and drug manufacturers’ compatibility data sheets are also recommended sources for Y‑site compatibility verification. (Annals of Emergency Medicine) 4

In humans with acute anticoagulant rodenticide poisoning, intramuscular injection of vitamin K₁ is recommended over subcutaneous injection because subcutaneous absorption is unpredictable and the therapeutic response is delayed. The American College of Cardiology advises this route to ensure reliable correction of coagulopathy. 5

Subcutaneous administration should not be used as the sole route for vitamin K₁ in this setting, as erratic absorption can postpone normalization of clotting parameters and increase the risk of ongoing bleeding. The American College of Cardiology cautions against reliance on this method. 5

Routine use of high‑dose vitamin K₁ (>10 mg) in non‑emergent situations is discouraged; doses ≥10 mg can induce a transient warfarin‑resistance state lasting up to one week and may over‑correct coagulation, potentially leading to thrombotic complications. The American College of Cardiology recommends limiting high‑dose use to life‑threatening hemorrhage only. 5

Intravenous vitamin K₁ should be reserved for life‑threatening hemorrhage because of the risk of anaphylaxis. When IV delivery is unavoidable, the drug should be diluted in 25–50 mL of normal saline and infused slowly over 15–30 minutes. Premedication with prednisolone at 1 mg/kg is advised to mitigate anaphylactic reactions. The American College of Cardiology outlines this protocol to enhance safety. 5